Rebel Medicine Inc has closed a $6 million Series A financing led by Crocker Ventures to advance its non-opioid pain therapeutic Alevatrix™ into clinical development.
Rebel Medicine Inc has closed a $6 million Series A financing led by Crocker Ventures to advance its non-opioid pain therapeutic Alevatrix™ into clinical development.
06/12/25, 2:16 PM
Location
salt lake cityMoney raised
$6 million
Industry
health care
Round Type
series a
Investors
Cantina Angels, The Joan & Tim Fenton Fund, Sk Hart, Utah Innovation Fund, Prosperity Solutions Capital, Central Texas Angel Network (Ctan), Crocker Ventures
Rebel Medicine Inc, a clinical-stage biotechnology company, announced the closing of its $6 million Series A financing. Led by Crocker Ventures, the financing will help advance Alevatrix™, their non-opioid pain drug candidate, into clinical trials. The funding coincides with their IND application opening with the FDA. This successful fundraise validates their vision and accelerates the clinical development of their technologies.